CA1148166A - Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions - Google Patents
Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositionsInfo
- Publication number
- CA1148166A CA1148166A CA000372315A CA372315A CA1148166A CA 1148166 A CA1148166 A CA 1148166A CA 000372315 A CA000372315 A CA 000372315A CA 372315 A CA372315 A CA 372315A CA 1148166 A CA1148166 A CA 1148166A
- Authority
- CA
- Canada
- Prior art keywords
- propionic acid
- phenyl
- mean
- aryl
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Abstract
ESTERS OF ARYLPROPIONIC ACIDS ENDOWED WITH AN ANTI-INFLAMMATORY
ACTIVITY, PROCESS FOR THEIR PREPARATION, AND RELATED
PHARMACEUTICAL COMPOSITIONS.
ABSTRACT OF THE DISCLOSURE
The present invention concerns diesters of polyethylene glycols (with n ranging between 4 approximately and 100 approximately) with 2-arylpropionic acids (known as anti-inflammatory agents). Said esters, while possessing all the characteristics of low toxicity and gastric injuring effects shown by the related acids, differ advantageously from the latter because their anti-inflammatory activity is much more prolonged, and their bioavailability markedly better.
ACTIVITY, PROCESS FOR THEIR PREPARATION, AND RELATED
PHARMACEUTICAL COMPOSITIONS.
ABSTRACT OF THE DISCLOSURE
The present invention concerns diesters of polyethylene glycols (with n ranging between 4 approximately and 100 approximately) with 2-arylpropionic acids (known as anti-inflammatory agents). Said esters, while possessing all the characteristics of low toxicity and gastric injuring effects shown by the related acids, differ advantageously from the latter because their anti-inflammatory activity is much more prolonged, and their bioavailability markedly better.
Description
8~
DESCRIPTION OF THE INVENTr The present invention concerns. new esters of aryl-propionlc acids, characterized by the general formula (I) R' ~ CH-C-0-(CH2CH~O)n-C-IH - ~
R" 1~"
(I) where n represents a number ranging between 4 approximately and 100 approximately while R' may be a hydrogen atom (in which case R" represents the isobutyl, benzoyl, 2-tenoyl or l-oxo-2-isoindolinyl residue) or R' may be a phenyl group (in which case R" represents a fluorine atom or still R' and R" represent together a benæene ring orthocondensated on the first ring, and carrying a methoxyl group. R' and R", preferably, are such as that tI) represents diesters of polyethylene glycols with the 2-(4-isobutyl-phenyl)-, 2-[4-(2-tenoyl)-phenyl]-,2-[4-(1-oxo-2-isoindolinyl)phenyl]-,
DESCRIPTION OF THE INVENTr The present invention concerns. new esters of aryl-propionlc acids, characterized by the general formula (I) R' ~ CH-C-0-(CH2CH~O)n-C-IH - ~
R" 1~"
(I) where n represents a number ranging between 4 approximately and 100 approximately while R' may be a hydrogen atom (in which case R" represents the isobutyl, benzoyl, 2-tenoyl or l-oxo-2-isoindolinyl residue) or R' may be a phenyl group (in which case R" represents a fluorine atom or still R' and R" represent together a benæene ring orthocondensated on the first ring, and carrying a methoxyl group. R' and R", preferably, are such as that tI) represents diesters of polyethylene glycols with the 2-(4-isobutyl-phenyl)-, 2-[4-(2-tenoyl)-phenyl]-,2-[4-(1-oxo-2-isoindolinyl)phenyl]-,
2-(3-benzoyl-phenyl)-, 2-(3-fluoro-4-phenyl-phenyl) - and 2-(6-methoxy-2-naphthyl)-propionic acids that are all known for their anti-inflammatory properties. Preferably, moreover, _ takes mean values ranging between 10 approximately and 50 approximately. The present invention, moreover, also concerns the enantiomers of the esters characterized by the formula (I).
The compounds (I), comparable to the corresponding acids with respect to their properties of low toxicity and gastric injuring effects, present with an anti-inflammatory activity that, although showing an equivalent intensity, differs markedly for a more prolonged duration. This 11~8~66 evidence constitutes a considerable advantage since the corresponding acids are generally characterized by a short-texm action. Also pharmacokinetic investigations show a bioavailability markedly higher, even of a 100 percent rate, than that shown by the corresponding acids. Therefore, a further object of the present invention is represented by pharmaceutical compositions endowed with an anti-inflammatory activity, containing as active ingredient at least one ester of formula (I), in the form of a racemus or of enantiomers-An additional object of the present invention is represented by a procedure for the preparation of the esters (I), that consists in reacting the compounds of formula (II) CH-~OX (II) R"
where R' and R" have the above stated significance while X
represents either a hydroxyl group or preferably an activating group such~an alkoxyl, Cl, l-imidazolyl group or still a residue apt to form, with the remaining moiety of the mole-cule, an anhydride function), with a polyethylene glycol, characterized by the formula HO-(CH2CH2O)n-H, where n has the above stated significance, preferably ranging (as mean value) between 10 approximately and S0 approximately. Pre-ferably, the compounds (II) are brought into reaction with polyethylene glycols in a molar ratio of 2:1 approximately, preferably around 2.5:1, in order to ensure the maximum diester yield.
.~
The below reported example duly illustrates the invention, constituting however no limitation to its scope.
_.MPLE 1 Die~ster of 2-(4-isobutyl-phenyl)propionic acid with poly-ethylene glycol 1000 (n=20, 3 in the mean).
~ ~ cH c o(cH2cH2o)n c cH ~ 7 R
where R=isobutyl; n=20.3 (in the mean) 21 grams (0.102 moles) of 2-(4-isobutyl-phenyl)propionic acid (ibuprofen) are dissolved in 300 ml of anhydrous CHC13. The resulting solution is added with 21 g of carbonyl-diimidazole (CDI, 0.13 moles) under agitation, at room temperature. As soon as the effervescence is terminated (half-an-hour approximately), the reaction mixture is added with 40 g of polyethylene glycol 1000 (0.4 moles) previously dried under vacuum at 30C and dissolved in 200 ml of anhydrous CHC13.
The reaction is caused to occur in a thermostatized bath at 60C for 48 hours. The excess of ibuprofen results to be 25 percent approximately with respect to the quantity - required for the formation of the diester.
The resulting solution is washed two times with 20 100 ml of water, two times with 100 ml of 0.1 N HCl, two further times with 100 ml of water, still two times with 100 ml of 0.1 N NaOH, and finally three times with 100 ml of water.
After drying on Na2SO4, the solution is filtered and concentrated under vacuum. The concentrated solution is shaken with anhydrous n-heptane (about 1000 ml); n-heptane is then decanted, and anhydrous ethyl ether (500 ml approxi-mately) is added cooling down to 0-5C in order to reduce to a minimum the solubility of the diester.
After further decantation, the product is dried under vacuum (0.1 mm Hg). The product solidifies, taking a waxy consistence, only after elimination of any trace of solvent. Yield 40 g (73 percent).
On the basis of the NMR spectrum (Figure 1) the overall rate of esterification results to correspond to 25 percent in weight of ibuprofen that can be liberated. This datum proves comparable with the one provided by the indirect titration (theoretical: 1.67 meq; practical: 1.525 meq., equivalent to 27.3 percent of ibuprofen that can be liberated);
moreover, the direct titration indicates the absence of un-bound ibuprofen.
The resulting product (that for brevity's sake shall be from now on called with the code name MR-654) is scarcely soluble in water, in aliphatic hydrocarbons and in diethylether, soluble in methanol, ethanol and acetone. Its TLC characteristics shall be reported further on.
Diester of 2-(4-isobutyl-phenyl)propionic acid with poly-ethylene glycol 2000 (n = 43.04 in the mean) C~3 C~
R __ ~ H-c-O(c~2cH2o)~-c-cH -where R = isobutyl; n = 43.04 (in the mean) As analogously as in Example 1, 11 g of ibuprofen (0.053 moles) are dissolved in 150 ml of anhydrous CHC13.
.~ ' .
The resulting solution is added with 11 g of CDI (0.068 moles), under agitation at room temperature.
As soon as the effervescence is terminated (half-anwhour approximately), the reaction mixture is added with 40 g of polyethylene glycol 2000 (0.02 moles), previously dried under vacuum at 30C, dissolved in 200 ml of anhydrous CHC13. The excess of ibuprofen results to be 33 percent approximately with respect to the desubstitution of poly-ethylene glycol 2000. The reaction is caused to occur in a thermostatized bath at 68C for 48 hours.
The chloroform solution is washed two times with 100 ml of water, two times with 100 ml of 0.1 N HCl, two further times with 100 ml of water, still two times with 100 ml of 0.1 N NaOH, and finally three times with 100 ml of water. After drying on Na2S04, the resulting solution is filtered and concentrated under vacuum. The product is precipitated by addition, to the concentrated solution, of 1 liter of a 2:1 n-heptane/ether mixture (anhydrous solvents).
The precipitate is filtered by pump and dried under vacuum (0.1 mmHg). Yield 42 g (88 percent).
On the basis of the NMR spectrum (FIGURE 2) the overall esterification rate results to correspond to 15~percent approximately, in weight, of Ibuprofen that can be liberated.
This datum coincides with the datum resulting from the in-direct titration (theoretical:0.85 meq; practical:0.75 meq.);
moreover the direct titration proves the absence of unbound ibuprofen.
The resulting product (that, for brevity's sake shall be defined from now on with the code name MR-655) is scarcely soluble in aliphatic hydrocarbons and in diethyl-..~,i~
1~48~6~
ether, soluble in water, alcohols and acetone. The diesters MR 654 and MR-655 were subjected to chromatography on Merck 60 Kieselgel plates; the elution was carried out wi~h a MeOH/
CHC13/glacial AcOH in a 70:35:4 ratio.
Ibuprofen, polyglycols and diesters present with the following coefficients of retention:
Rf MR-654 0.68 MR-655 0.47 ~buprofen 0.78 PEG 1000 0.4 PEG 2000 0.32 The spots, pertaining to the two oligomeric derivatives (I) are single. TLC does not reveal in any case the presence of unbound ibuprofen. The replication of the preparations of the products MR-654 and MR-655 allowed to remark their reproducibility.
The pharmacotoxicologic properties of the diesters (I) are hereinbelow described on the basis of the examples provided by the compounds MR-654 and MR-655.
ACUTE TOXICITY
The acute toxicity of the two products, established orally in the mouse, provided LD50 values higher than 2a00 mg/kg. Also the gastric injuring effects of MR-654 and MR-655 result to be very low, i.e. mildly lower than those induced by ibuprofen.
ANTI-INFLAMMATORY ACTIVITY
The anti-inflammatory activity of MR-654 and MR-655 was assessed in comparison with that of ibuprofen, at equi-molar doses, by the carrageenin edema test in the rat (Wistarmale and female animals, bodyweight of 160-200 g; twelve ~148166 animals for each compound and for each experiment). One percent carrageenin in saline was injected, at the dosage rate of 0.1 ml, subcutaneously, into the plantar area of the left paw. Ibuprcfen was given at doses of 100 mg/kg/os (in 5 percent gum arabic); MR-654 and MR-655 were given in doses equivalent to 100 mg/kg/os of ibuprofen, i.e. of 370 and 625 mg/kg/os.
The products were administered 1, 3 and 6 hours respectively before the carrageenin injection; the values were always read 4 hours after the injection of carrageenin assessing the percent swelling of the paw versus the value observed at the time O (carrageenin inocule). The results were expressed in terms of percent protection considering the swelling, observed in the control group, as equal to 100 .
The protection exerted by the investigational com-pounds is expressed in the attached Table 1, which enables to remark that the anti-inflammatory action of MR-654 and MR-655 is exerted according to a typical slow release effect.
Percent protection from the carrageenin edema after oral administration, in the rat, of ibuprofen, MR-654 and MR-655, control groups being made equal to 100.
Product Detection after hours Ibuprofen 60 4428 24 20 Actually, the activity of ibuprofen results to be much higher than that exerted by the other two compounds at the first hour; but, already starting from the second hour, '.~
~14816ti the new related values can be considered almost comparable.
From third hour on, a quite different pattern is observed, i.e.:
- the activity of ibuprofen decreases markedly and constantly;
- MR-654 attains in these detections a maximum peak of efficacy that results to be prolonged in the course of time keeping, despite a dropping parabola, values always markedly higher than those provided by ibuprofen;
- in the case of MR-655, progressively from the third hour, the line of activity increases gradually and markedly through an evident delayed release.
PHARMACOKINETICS
The plasma pharmacokinetics of MR-654 and MR-655 was investigated following oral administration in the albino rat, Wistar strain, male sex, bodyweight ranging between 180 and 220 grams. Since said compounds liberate ibuprofen into the body, the kinetics of said latter drug was also investi-gated at the doses of 58.8 mg/kg and 19.2 mg/kg.
In the case of ibuprofen, the plasma kinetics was also investigated after oral administration to the purpose of being provided with an assessment of the rate of intestinal absorption of this drug.
The investigational compounds were given by oral gavage, suspended in 0.5 percent gum arabic; an analogous suspension was also used in the case of intraperitoneal administration. Blood withdrawals from the animals were made from a sublingual vein, according to the procedure described by Ferro Milone M and Barbiera P. ~Atti della Soc.
It.Scienze Veterinarie, 1974, 28, 394).
~8166 The plasma determination o~ ibuprofen was carried out by a gas chromatographic method accord;`n~ to the procedure descri~ed by Runci F.M. and Segre G. (Recent Development in Chromatography and Electrophoresis, A.Frigerio, L.Renoz Eds., Elsevier, Amsterdam, 1~79, page 199).
Table 2 shows the plasma kinetic patterns after oral and intraperitoneal administration of 58.8 mg/kg, and after oral administration of 19.2 mg/kg. The intraperitoneal kinetics, provided that it can be assimilated to the intra-venous kinetics, can be expressed by the following biexpon-ential equation:
X(t) = 468 e~2 1t+32 e-0.23t where X = concentration as mcg/ml and t = hours.
The half-life, calculated on the basis of the second component, results to be equivalent to 3 hours approximately.
The areas under the curve (AUC) are in a first approximation (for times up to the 7th hour) equivalent to 190 (os) and 325 (ip), in a ratio equivalent to a 60 percent level.
The kinetic patterns of MR-654 and MR-655 are shown in Table 2; the content of ibuprofen of the two molecules is such that the used dose of MR-654, equivalent to 120~mg/kg, corresponds to 38.8 mg/kg of ibuprofen while the dose of MR-655, equivalent to 19.2 mg/kg, corresponds to 19.2 mg/kg of ibuprofen.
On the basis of said content of ibuprofen, the plasma curves were compared with the curves resulting from the administration of 58.8 and 1~.2 mg/kg of ibuprofen. In the case of MR-654 the comparison was also made with said two doses of ibuprofen since the plasma kinetics of ibuprofen ~8~66 had not been investigated at the dose of 38.8 mg/kg. A line going through the peaks (at the first hourl of the plasma le~els of ibuprofen at the two tested doses (58.8 and 19. 2 mg/kg) was plotted in order to better assess the kinetic patterns. It could be stated on the basis of said line that MR-654 and MR-655 present with a slower drop of the plasma concentration after the peak (and therefore a longer half-life) and can therefore be considered as long-acting ibuprofen.
Plasma concentrations and standard deviations (mcg/ml) of ibuprofen in the male rat, after intraperitoneal and oral administration of MR-654, and oral administration of MR-655.
.
Product Dose given 0.5 hour of adm~nistration mg/k~ 1 2 5 7 Ibuprofen os 19.2 26.2- 10. 5- 0.12+
9.7 1.9 0.03 Ibuprofen i.p, 58.8 215.2-104.7- 18.3- 6.2-33.4 12.4 11.0 2.4 Ibuprofen os 58.8 71.7- 34.2- 12.1- 9.1-23.6 7.7 2.2 1.5 MF<-654 os 120(*)116.1-39.3-12.9- 10. 7-11.7 14.2 3.5 3.0 MR-655 os 120(**) 13.4- 10.9- 7. 5-7. 2-2.1 2.7 0.30.4 ;
(*) correspondent to 38.8 mg of ibuprofen (**) correspondent to 19.2 mg of ibuprofen
The compounds (I), comparable to the corresponding acids with respect to their properties of low toxicity and gastric injuring effects, present with an anti-inflammatory activity that, although showing an equivalent intensity, differs markedly for a more prolonged duration. This 11~8~66 evidence constitutes a considerable advantage since the corresponding acids are generally characterized by a short-texm action. Also pharmacokinetic investigations show a bioavailability markedly higher, even of a 100 percent rate, than that shown by the corresponding acids. Therefore, a further object of the present invention is represented by pharmaceutical compositions endowed with an anti-inflammatory activity, containing as active ingredient at least one ester of formula (I), in the form of a racemus or of enantiomers-An additional object of the present invention is represented by a procedure for the preparation of the esters (I), that consists in reacting the compounds of formula (II) CH-~OX (II) R"
where R' and R" have the above stated significance while X
represents either a hydroxyl group or preferably an activating group such~an alkoxyl, Cl, l-imidazolyl group or still a residue apt to form, with the remaining moiety of the mole-cule, an anhydride function), with a polyethylene glycol, characterized by the formula HO-(CH2CH2O)n-H, where n has the above stated significance, preferably ranging (as mean value) between 10 approximately and S0 approximately. Pre-ferably, the compounds (II) are brought into reaction with polyethylene glycols in a molar ratio of 2:1 approximately, preferably around 2.5:1, in order to ensure the maximum diester yield.
.~
The below reported example duly illustrates the invention, constituting however no limitation to its scope.
_.MPLE 1 Die~ster of 2-(4-isobutyl-phenyl)propionic acid with poly-ethylene glycol 1000 (n=20, 3 in the mean).
~ ~ cH c o(cH2cH2o)n c cH ~ 7 R
where R=isobutyl; n=20.3 (in the mean) 21 grams (0.102 moles) of 2-(4-isobutyl-phenyl)propionic acid (ibuprofen) are dissolved in 300 ml of anhydrous CHC13. The resulting solution is added with 21 g of carbonyl-diimidazole (CDI, 0.13 moles) under agitation, at room temperature. As soon as the effervescence is terminated (half-an-hour approximately), the reaction mixture is added with 40 g of polyethylene glycol 1000 (0.4 moles) previously dried under vacuum at 30C and dissolved in 200 ml of anhydrous CHC13.
The reaction is caused to occur in a thermostatized bath at 60C for 48 hours. The excess of ibuprofen results to be 25 percent approximately with respect to the quantity - required for the formation of the diester.
The resulting solution is washed two times with 20 100 ml of water, two times with 100 ml of 0.1 N HCl, two further times with 100 ml of water, still two times with 100 ml of 0.1 N NaOH, and finally three times with 100 ml of water.
After drying on Na2SO4, the solution is filtered and concentrated under vacuum. The concentrated solution is shaken with anhydrous n-heptane (about 1000 ml); n-heptane is then decanted, and anhydrous ethyl ether (500 ml approxi-mately) is added cooling down to 0-5C in order to reduce to a minimum the solubility of the diester.
After further decantation, the product is dried under vacuum (0.1 mm Hg). The product solidifies, taking a waxy consistence, only after elimination of any trace of solvent. Yield 40 g (73 percent).
On the basis of the NMR spectrum (Figure 1) the overall rate of esterification results to correspond to 25 percent in weight of ibuprofen that can be liberated. This datum proves comparable with the one provided by the indirect titration (theoretical: 1.67 meq; practical: 1.525 meq., equivalent to 27.3 percent of ibuprofen that can be liberated);
moreover, the direct titration indicates the absence of un-bound ibuprofen.
The resulting product (that for brevity's sake shall be from now on called with the code name MR-654) is scarcely soluble in water, in aliphatic hydrocarbons and in diethylether, soluble in methanol, ethanol and acetone. Its TLC characteristics shall be reported further on.
Diester of 2-(4-isobutyl-phenyl)propionic acid with poly-ethylene glycol 2000 (n = 43.04 in the mean) C~3 C~
R __ ~ H-c-O(c~2cH2o)~-c-cH -where R = isobutyl; n = 43.04 (in the mean) As analogously as in Example 1, 11 g of ibuprofen (0.053 moles) are dissolved in 150 ml of anhydrous CHC13.
.~ ' .
The resulting solution is added with 11 g of CDI (0.068 moles), under agitation at room temperature.
As soon as the effervescence is terminated (half-anwhour approximately), the reaction mixture is added with 40 g of polyethylene glycol 2000 (0.02 moles), previously dried under vacuum at 30C, dissolved in 200 ml of anhydrous CHC13. The excess of ibuprofen results to be 33 percent approximately with respect to the desubstitution of poly-ethylene glycol 2000. The reaction is caused to occur in a thermostatized bath at 68C for 48 hours.
The chloroform solution is washed two times with 100 ml of water, two times with 100 ml of 0.1 N HCl, two further times with 100 ml of water, still two times with 100 ml of 0.1 N NaOH, and finally three times with 100 ml of water. After drying on Na2S04, the resulting solution is filtered and concentrated under vacuum. The product is precipitated by addition, to the concentrated solution, of 1 liter of a 2:1 n-heptane/ether mixture (anhydrous solvents).
The precipitate is filtered by pump and dried under vacuum (0.1 mmHg). Yield 42 g (88 percent).
On the basis of the NMR spectrum (FIGURE 2) the overall esterification rate results to correspond to 15~percent approximately, in weight, of Ibuprofen that can be liberated.
This datum coincides with the datum resulting from the in-direct titration (theoretical:0.85 meq; practical:0.75 meq.);
moreover the direct titration proves the absence of unbound ibuprofen.
The resulting product (that, for brevity's sake shall be defined from now on with the code name MR-655) is scarcely soluble in aliphatic hydrocarbons and in diethyl-..~,i~
1~48~6~
ether, soluble in water, alcohols and acetone. The diesters MR 654 and MR-655 were subjected to chromatography on Merck 60 Kieselgel plates; the elution was carried out wi~h a MeOH/
CHC13/glacial AcOH in a 70:35:4 ratio.
Ibuprofen, polyglycols and diesters present with the following coefficients of retention:
Rf MR-654 0.68 MR-655 0.47 ~buprofen 0.78 PEG 1000 0.4 PEG 2000 0.32 The spots, pertaining to the two oligomeric derivatives (I) are single. TLC does not reveal in any case the presence of unbound ibuprofen. The replication of the preparations of the products MR-654 and MR-655 allowed to remark their reproducibility.
The pharmacotoxicologic properties of the diesters (I) are hereinbelow described on the basis of the examples provided by the compounds MR-654 and MR-655.
ACUTE TOXICITY
The acute toxicity of the two products, established orally in the mouse, provided LD50 values higher than 2a00 mg/kg. Also the gastric injuring effects of MR-654 and MR-655 result to be very low, i.e. mildly lower than those induced by ibuprofen.
ANTI-INFLAMMATORY ACTIVITY
The anti-inflammatory activity of MR-654 and MR-655 was assessed in comparison with that of ibuprofen, at equi-molar doses, by the carrageenin edema test in the rat (Wistarmale and female animals, bodyweight of 160-200 g; twelve ~148166 animals for each compound and for each experiment). One percent carrageenin in saline was injected, at the dosage rate of 0.1 ml, subcutaneously, into the plantar area of the left paw. Ibuprcfen was given at doses of 100 mg/kg/os (in 5 percent gum arabic); MR-654 and MR-655 were given in doses equivalent to 100 mg/kg/os of ibuprofen, i.e. of 370 and 625 mg/kg/os.
The products were administered 1, 3 and 6 hours respectively before the carrageenin injection; the values were always read 4 hours after the injection of carrageenin assessing the percent swelling of the paw versus the value observed at the time O (carrageenin inocule). The results were expressed in terms of percent protection considering the swelling, observed in the control group, as equal to 100 .
The protection exerted by the investigational com-pounds is expressed in the attached Table 1, which enables to remark that the anti-inflammatory action of MR-654 and MR-655 is exerted according to a typical slow release effect.
Percent protection from the carrageenin edema after oral administration, in the rat, of ibuprofen, MR-654 and MR-655, control groups being made equal to 100.
Product Detection after hours Ibuprofen 60 4428 24 20 Actually, the activity of ibuprofen results to be much higher than that exerted by the other two compounds at the first hour; but, already starting from the second hour, '.~
~14816ti the new related values can be considered almost comparable.
From third hour on, a quite different pattern is observed, i.e.:
- the activity of ibuprofen decreases markedly and constantly;
- MR-654 attains in these detections a maximum peak of efficacy that results to be prolonged in the course of time keeping, despite a dropping parabola, values always markedly higher than those provided by ibuprofen;
- in the case of MR-655, progressively from the third hour, the line of activity increases gradually and markedly through an evident delayed release.
PHARMACOKINETICS
The plasma pharmacokinetics of MR-654 and MR-655 was investigated following oral administration in the albino rat, Wistar strain, male sex, bodyweight ranging between 180 and 220 grams. Since said compounds liberate ibuprofen into the body, the kinetics of said latter drug was also investi-gated at the doses of 58.8 mg/kg and 19.2 mg/kg.
In the case of ibuprofen, the plasma kinetics was also investigated after oral administration to the purpose of being provided with an assessment of the rate of intestinal absorption of this drug.
The investigational compounds were given by oral gavage, suspended in 0.5 percent gum arabic; an analogous suspension was also used in the case of intraperitoneal administration. Blood withdrawals from the animals were made from a sublingual vein, according to the procedure described by Ferro Milone M and Barbiera P. ~Atti della Soc.
It.Scienze Veterinarie, 1974, 28, 394).
~8166 The plasma determination o~ ibuprofen was carried out by a gas chromatographic method accord;`n~ to the procedure descri~ed by Runci F.M. and Segre G. (Recent Development in Chromatography and Electrophoresis, A.Frigerio, L.Renoz Eds., Elsevier, Amsterdam, 1~79, page 199).
Table 2 shows the plasma kinetic patterns after oral and intraperitoneal administration of 58.8 mg/kg, and after oral administration of 19.2 mg/kg. The intraperitoneal kinetics, provided that it can be assimilated to the intra-venous kinetics, can be expressed by the following biexpon-ential equation:
X(t) = 468 e~2 1t+32 e-0.23t where X = concentration as mcg/ml and t = hours.
The half-life, calculated on the basis of the second component, results to be equivalent to 3 hours approximately.
The areas under the curve (AUC) are in a first approximation (for times up to the 7th hour) equivalent to 190 (os) and 325 (ip), in a ratio equivalent to a 60 percent level.
The kinetic patterns of MR-654 and MR-655 are shown in Table 2; the content of ibuprofen of the two molecules is such that the used dose of MR-654, equivalent to 120~mg/kg, corresponds to 38.8 mg/kg of ibuprofen while the dose of MR-655, equivalent to 19.2 mg/kg, corresponds to 19.2 mg/kg of ibuprofen.
On the basis of said content of ibuprofen, the plasma curves were compared with the curves resulting from the administration of 58.8 and 1~.2 mg/kg of ibuprofen. In the case of MR-654 the comparison was also made with said two doses of ibuprofen since the plasma kinetics of ibuprofen ~8~66 had not been investigated at the dose of 38.8 mg/kg. A line going through the peaks (at the first hourl of the plasma le~els of ibuprofen at the two tested doses (58.8 and 19. 2 mg/kg) was plotted in order to better assess the kinetic patterns. It could be stated on the basis of said line that MR-654 and MR-655 present with a slower drop of the plasma concentration after the peak (and therefore a longer half-life) and can therefore be considered as long-acting ibuprofen.
Plasma concentrations and standard deviations (mcg/ml) of ibuprofen in the male rat, after intraperitoneal and oral administration of MR-654, and oral administration of MR-655.
.
Product Dose given 0.5 hour of adm~nistration mg/k~ 1 2 5 7 Ibuprofen os 19.2 26.2- 10. 5- 0.12+
9.7 1.9 0.03 Ibuprofen i.p, 58.8 215.2-104.7- 18.3- 6.2-33.4 12.4 11.0 2.4 Ibuprofen os 58.8 71.7- 34.2- 12.1- 9.1-23.6 7.7 2.2 1.5 MF<-654 os 120(*)116.1-39.3-12.9- 10. 7-11.7 14.2 3.5 3.0 MR-655 os 120(**) 13.4- 10.9- 7. 5-7. 2-2.1 2.7 0.30.4 ;
(*) correspondent to 38.8 mg of ibuprofen (**) correspondent to 19.2 mg of ibuprofen
Claims (26)
1. Process for the preparation of esters of aryl-propionic acids of the formula (I) (I) where n represents a number ranging between 4 approximately and 100 approximately, while R' may be a hydrogen atom (in which case R" may represent the isobutyl, benzoyl, 2-tenoyl or 1-oxo-2-isoindolinyl residue) or R' may be a phenyl group (in which case R" represents a fluorine atom) or still R' and R" may represent together a benzene ring orthocondensated on the first ring, and carrying a methoxyl group as well as their enantiomers, characterized by the fact that compounds of the formula (II) (II) where R' and R" have the above stated significance while X
represents a hydroxyl group or, preferably, an activating group such an alkoxyl group, a C1 atom, a 1-imidazolyl group or still a residue apt to form an anhydride function with the remaining moiety of the molecule, are brought into reaction with a polyethylene glycol, characterized by the formula HO-(CH2CH2O)n-H, where n represents a number ranging between 4 approximately and 100 approximately, the molar ratio between (II) and polyglycol being approximately 2.5:1.
represents a hydroxyl group or, preferably, an activating group such an alkoxyl group, a C1 atom, a 1-imidazolyl group or still a residue apt to form an anhydride function with the remaining moiety of the molecule, are brought into reaction with a polyethylene glycol, characterized by the formula HO-(CH2CH2O)n-H, where n represents a number ranging between 4 approximately and 100 approximately, the molar ratio between (II) and polyglycol being approximately 2.5:1.
2. Process according to claim 1, wherein the aryl-propionic acid is 2-(4-isobutyl-phenyl)propionic acid and n is 20.3 in the mean.
3. Process according to claim 1, wherein the aryl-propionic acid is 2-(4-isobutyl-phenyl)propionic acid and n is 43.04 in the mean.
4. Process according to claim 1, wherein the aryl-propionic acid is 2-[4-(2-tenoyl)phenyl]propionic acid and n is 20.3 in the mean.
5. Process according to claim 1, wherein the aryl-propionic acid is 2-[4-(2-tenoyl)phenyl]propionic acid and n is 43.04 in the mean.
6. Process according to claim 1, wherein the aryl-propionic acid is 2-[4-(1-oxo-2-isoindolinyl)phenyl]propionic acid and n is 20.3 in the mean.
7. Process according to claim 1, wherein the aryl-propionic acid is 2-[4-(1-oxo-2-isoindolinyl)phenyl]propionic acid and n is 43.04 in the mean.
8. Process according to claim 1, wherein the aryl-propionic acid is 2-(3-benzoyl-phenyl)propionic acid and n is 20.3 in the mean.
9. Process according to claim 1, wherein the aryl-propionic acid is 2-(3-benzoyl-phenyl)propionic acid and n is 43.04 in the mean.
10. Process according to claim 1, wherein the aryl-propionic acid is 2-(3-fluoro-4-phenyl-phenyl)propionic acid and n is 20.3 in the mean.
11. Process according to claim 1, wherein the aryl-propionic acid is 2-(3-fluoro-4-phenyl-phenyl)propionic acid and n is 43.04 in the mean.
12. Process according to claim 1, wherein the aryl-propionic acid is 2-(6-methoxy-2-naphthyl)propionic acid and n is 20.3 in the mean.
13. Process according to claim 1, wherein the aryl-propionic acid is 2-(6-methoxy-2-naphthyl)propionic acid and n is 43.04 in the mean.
14. Esters of arylpropionic acids of the formula (I) (I) where n represents a number ranging between 4 approximately and 100 approximately, while R' may be a hydrogen atom (in which case R" may represent the isobutyl, benzoyl, 2-tenoyl or l-oxo-2-isoindolinyl residue) or R' may be a phenyl'group (in which case R" represents a fluorine atom) or still R' and R" may represent together a benzene ring orthocondensated on the first ring, and carrying a methoxyl group as well as their enantiomers, whenever obtained by the process as claimed in claim 1, or by an obvious chemical equivalent thereof.
15. Diester of 2-(4-isobutyl-phenyl)propionic acid with polyethylene glycol 1000 (n=20.3 in the mean), whenever obtained by the process as claimed in Claim 2, or by an obvious chemical equivalent thereof.
16. Diester of 2-(4-isobutyl-phenyl)propionic acid with polyethylene glycol 2000 (n= 43.04 in the mean), whenever obtained by the process as claimed in claim 3, or by an obvious chemical equivalent thereof.
17. Diester of 2-[4-(2-tenoyl)phenyl]propionic acid with polyethylene glycol 1000 (n = 20.3 in the mean), whenever obtained by the process as claimed in claim 4, or by an obvious chemical equivalent thereof.
18. Diester of 2-[4-(2-tenoyl)phenyl]propionic acid with polyethylene glycol 2000 (n = 43.04 in the mean), when-ever obtained by the process as claimed in claim 5, or by an obvious chemical equivalent thereof.
19. Diester of 2-[4-(1-oxo-2-isoindolinyl)phenyl]propionic acid with polyethylene glycol 1000 (n = 20.3 in the mean), whenever obtained by the process as claimed in claim 6, or by an obvious chemical equivalent thereof.
20. Diester of 2-[4-(1-oxo-2-isoindolinyl)phenyl]propionic acid with polyethylene glycol 2000 (n = 43.03 in the mean), whenever obtained by the process as claimed in claim 7, or by an obvious chemical equivalent thereof.
21. Diester of 2-(3-benzoyl-phenyl)propionic acid with polyethylene glycol 1000 (n = 20.3 in the mean), whenever obtained by the process as claimed in claim 8, or by an obvious chemical equivalent thereof.
22. Diester of 2-(3-benzoyl-phenyl)propionic acid with polyethylene glycol 2000 (n = 43.03 in the mean), whenever obtained by the process as claimed in claim 9, or by an obvious chemical equivalent thereof.
23. Diester of 2-(3-fluoro-4-phenyl-phenyl)propionic acid with polyethylene glycol 1000 (n = 20.3 in the mean), whenever obtained by the process as claimed in claim 10, or by an obvious chemical equivalent thereof.
24. Diester of 2-(3-fluoro-4-phenyl-phenyl)propionic acid with polyethylene glycol 2000 (n = 43.03 in the mean), whenever obtained by the process as claimed in claim 11, or by an obvious chemical equivalent thereof.
25. Diester of 2-(6-methoxy-2-naphthyl)propionic acid with polyethylene glycol ]000 (n = 20.3 in the mean), when-ever obtained by the process as claimed in claim 12, or by an obvious chemical equivalent thereof.
26. Diester of 2-(6-methoxy-2-naphthyl)propionic acid with polyethylene glycol 2000 (n = 43.04 in the mean), when-ever obtained by the process as claimed in claim 13, or by an obvious chemical equivalent thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000372315A CA1148166A (en) | 1981-03-04 | 1981-03-04 | Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000372315A CA1148166A (en) | 1981-03-04 | 1981-03-04 | Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1148166A true CA1148166A (en) | 1983-06-14 |
Family
ID=4119379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000372315A Expired CA1148166A (en) | 1981-03-04 | 1981-03-04 | Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1148166A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196567A (en) * | 1983-02-19 | 1993-03-23 | Kaken Pharmaceutical Co., Ltd. | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same |
| US7208145B2 (en) | 2002-12-31 | 2007-04-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
| WO2021024041A1 (en) * | 2019-08-07 | 2021-02-11 | Ripple Therapeutics Corporation | Controlled release drug dimers |
| US11279729B2 (en) | 2020-05-01 | 2022-03-22 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
-
1981
- 1981-03-04 CA CA000372315A patent/CA1148166A/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196567A (en) * | 1983-02-19 | 1993-03-23 | Kaken Pharmaceutical Co., Ltd. | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same |
| US7208145B2 (en) | 2002-12-31 | 2007-04-24 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
| US8865149B2 (en) | 2002-12-31 | 2014-10-21 | Nektar Therapeutics | Polymeric reagents comprising a ketone or a related functional group |
| WO2021024041A1 (en) * | 2019-08-07 | 2021-02-11 | Ripple Therapeutics Corporation | Controlled release drug dimers |
| US11279729B2 (en) | 2020-05-01 | 2022-03-22 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tammara et al. | Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation | |
| US5023358A (en) | Vanadyl organo-mineral compound, method for obtaining such a compound, pharmaceutical composition containing this organo-mineral compound | |
| CA1148166A (en) | Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions | |
| US3984413A (en) | Phenoxyalkanecarboxylic acid esters of hydroxyalkyltheophyllines and method for their manufacture | |
| US4367176A (en) | Esters of arylpropionic acids endowed with an anti-inflammatory activity and related pharmaceutical compositions | |
| US4297357A (en) | N-Phenethylacetamide compounds and process for preparation thereof | |
| EP0129449B1 (en) | Diniflumate of morpholinoethyl ester of niflumic acid, its preparation, and its use in analgesic and antiinflammatory pharmaceutical compositions | |
| EP0080010B1 (en) | Novel compounds with antiinflammatory and analgesic activity, process for the preparation thereof and pharmaceutical compositions therefrom | |
| CA1148165A (en) | Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions | |
| US2860137A (en) | Xcoxz | |
| US4379091A (en) | Esters of arylpropionic acids endowed with an anti-inflammatory activity | |
| CA1072959A (en) | Quaternary sandwicine derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| US3971798A (en) | Pyridine derivative, processes of preparation and pharmaceutical compositions | |
| FR2478094A1 (en) | AMMONIO SUBSTITUTED CINNAMYLMORANOLINE DERIVATIVES WITH INHIBITION ACTIVITY OF SUGAR LEVEL IN BLOOD | |
| US4942176A (en) | N-substituted aminoalkanoic acids, a process for their preparation, their use and pharmaceutical products based on these compounds | |
| US4440786A (en) | Compounds with antiinflammatory and analgesic activity, process for the preparation thereof and pharmaceutical compositio ns therefrom | |
| US4075336A (en) | Thiazines and method | |
| FI65424C (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT VERKSAMMA DERIVAT AV NAFTALEN-AETTIKYYRA | |
| US4795758A (en) | 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present | |
| US4166125A (en) | 2-oxo-phenylbutanoic acid derivatives | |
| JPH062748B2 (en) | Novel hydantoin derivative and pharmaceutical composition containing the compound as an active ingredient | |
| US3288835A (en) | Substituted-carbamyl)-alk- oxyj-phenyl acetic acid esters | |
| JPS62187470A (en) | Tocopherol/tocotrienol-l-ascorbic acid-6-dicarboxylic acid diester, production thereof and drug containing said diester as active ingredient | |
| CA1173363A (en) | Pharmaceutical compositions having analgesic and anti-inflammatory activity | |
| GB2142015A (en) | 2-(4-biphenylyl)-4-hexenoic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |